NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld®) for treatment of COVID-19

Final draft guidance for remdesivir and for tixagevimab-cilgavimab has been published by the National Institute for Health and Care Excellence (NICE).

The Scottish Medicines Consortium (SMC) has had direct input into the decision-making committee that produced the final draft guidance. 

The final draft guidance recommends remdesivir as an option for treating COVID-19 in hospitals in specific patient groups.

Tixagevimab-cilgavimab (Evusheld®) is not recommended for treating COVID-19 in adults who do not need supplemental oxygen and who have an increased risk of progression to severe COVID-19.

The final published advice will have the same status for health board consideration as other SMC advice on new medicines.  SMC will issue a collaborative advice document to boards following publication of the NICE final guidance.

You can read more about the final draft guidance recommendations here: Final draft guidance: 2 | Project documents | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] | Guidance | NICE

Back to latest updates